Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals has reported Total Non-Current Liabilities for 18 years, with the latest figure at $5.9 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 4.41% year-over-year to $5.9 billion in Q2 2026; TTM through Jun 2026 was $5.9 billion, a 4.41% increase from a year earlier, with the FY2025 full-year figure at $5.7 billion, up 11.72% from the prior year.
• Total Non-Current Liabilities was $5.9 billion for Q2 2026 at Vertex Pharmaceuticals, up from $5.9 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $6.3 billion in Q3 2025, with the low at $3.2 billion in Q1 2022.
• Average Total Non-Current Liabilities over 5 years is $4.7 billion, with a median of $4.5 billion recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities surged 30.66% in 2024, then grew 4.41% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $3.6 billion in 2022, then grew by 20.26% to $4.3 billion in 2023, then grew by 19.59% to $5.1 billion in 2024, then climbed by 11.72% to $5.7 billion in 2025, then advanced by 3.64% to $5.9 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $5.9 billion (Q2 2026), $5.9 billion (Q1 2026), and $5.7 billion (Q4 2025), per Business Quant data.